iLIVER最新文献

{"title":"New approaches to the treatment of metabolic dysfunction-associated steatotic liver with natural products","authors":"Pooja Yadav ,&nbsp;Khushi Quadri ,&nbsp;Renu Kadian ,&nbsp;Aafrin Waziri ,&nbsp;Pankaj Agrawal ,&nbsp;Md Sabir Alam","doi":"10.1016/j.iliver.2024.100131","DOIUrl":"10.1016/j.iliver.2024.100131","url":null,"abstract":"<div><div>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a widespread and potentially severe liver condition characterized by abnormal fat accumulation in the liver unrelated to alcohol consumption. According to the World Health Organization, MASLD is the most prevalent liver disease globally, it affects approximately 25% of the world’s population, nearly two billion individuals. This staggering prevalence underscores the urgent need for effective and safe therapeutic approaches to address this escalating global health concern. Natural products have emerged as promising candidates for preventing and treating MASLD in recent years because of their diverse bioactive compounds and minimal side effects. Well-known natural products such as curcumin, resveratrol, green tea polyphenols, and silymarin exhibit notable hepatoprotective effects by influencing lipid metabolism, mitigating oxidative stress, and reducing inflammation. Ongoing research highlights the potential of phytochemicals from traditional medicinal plants, such as <em>Phyllanthus</em> and <em>Salvia</em>, in ameliorating liver steatosis and fibrosis. These natural products demonstrate the capacity to impede fibrogenesis by interfering with hepatic stellate cell activation, which is pivotal in liver fibrosis development. Recent studies underscore the significance of natural products in modulating the gut–liver axis, where they restore balance to the gut microbiota and enhance intestinal barrier function, which slows the progression of MASLD. Moreover, advancements in nanotechnology facilitate the targeted delivery of natural product-derived compounds, which enhances their bioavailability and therapeutic efficacy. Harnessing the potency of natural products offers a promising avenue for developing novel, safer therapies for MASLD and addressing a critical global health concern with far-reaching implications for public well-being.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 4","pages":"Article 100131"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142748567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Full robotic whole graft liver transplantation: Is a new era coming?","authors":"Yipeng Pan ,&nbsp;Jimin Liu ,&nbsp;Qi Ling","doi":"10.1016/j.iliver.2024.100128","DOIUrl":"10.1016/j.iliver.2024.100128","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 4","pages":"Article 100128"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142748569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Speaking the same language in predicting Small-for-Size Syndrome in living donor liver transplantation","authors":"Alfred Wei-Chieh Kow","doi":"10.1016/j.iliver.2024.100129","DOIUrl":"10.1016/j.iliver.2024.100129","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 4","pages":"Article 100129"},"PeriodicalIF":0.0,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142707081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the role of IER3+ macrophages in the prognosis of liver fibrosis by bulk and single-cell transcriptional analyses","authors":"Ling Chu ,&nbsp;Junbo Zhang ,&nbsp;Ruoyu Meng ,&nbsp;Quan Zhuang","doi":"10.1016/j.iliver.2024.100132","DOIUrl":"10.1016/j.iliver.2024.100132","url":null,"abstract":"<div><h3>Background and aims</h3><div>Liver fibrosis (LF) is the common pathological process of almost all liver diseases, but the pathogenesis is extremely complicated and has not been fully clarified. Therefore, we want to explore LF's complex pathogenesis and identify key genetic markers that can predict LF prognosis.</div></div><div><h3>Methods</h3><div>From Gene Expression Omnibus (GEO, <span><span>https://www.ncbi.nlm.nih.gov/geo/</span><svg><path></path></svg></span>), we contained datasets GSE84044 and GSE130970. And involved GSE15654 whose survival data were for the validation of our model’s prognostic value. Then, Bulk RNA sequencing was used to establish a LF-related prognostic model and to determine key genes.The key genes were later analyzed using single-cell RNA sequencing (scRNA-seq) and the role of macrophages in LF was investigated.</div></div><div><h3>Results</h3><div>We established a comprehensive LF-related prognostic model (FMSig, i.e., fibrosis macrophage-related prognostic signature) containing four genes (IER3, AKR1B10, ADCY1, and PGM1). FMSig can distinguish between survival outcomes in dataset GSE15654. IER3 showed a higher hazard ratio than the other three FMSig genes. Moreover, further scRNA-seq analysis showed that IER3 is highly expressed in myeloid cells while the other three genes were rarely expressed in six immune cell types and other cell clusters. After reclustering the myeloid cells into seven clusters, we found that IER3 was highly expressed in myeloid cell cluster 3, shown to be related to anti-inflammation and lipid metabolism functions. Based on pseudotime analysis, we suggest that myeloid cell type 3 is transformed from myeloid cell type 0 in the liver cirrhosis microenvironment. On immunohistochemical staining, LF showed significantly higher IER3 expression than healthy controls.</div></div><div><h3>Conclusion</h3><div>This study established a predictive model, FMSig, to evaluate LF prognosis, and showed that IER3 and macrophages are related to LF.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 4","pages":"Article 100132"},"PeriodicalIF":0.0,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142706992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “Clinical outcomes and histologic findings of patients with hepatocellular carcinoma with durable partial response or durable stable disease after receiving atezolizumab plus bevacizumab”","authors":"Binghua Li ,&nbsp;Qiang Wang ,&nbsp;Weiwei Hu ,&nbsp;Huan Li ,&nbsp;Peng Yan ,&nbsp;Yajuan Cao ,&nbsp;Decai Yu","doi":"10.1016/j.iliver.2024.100130","DOIUrl":"10.1016/j.iliver.2024.100130","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 4","pages":"Article 100130"},"PeriodicalIF":0.0,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142719874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Danning tablets for the treatment of multiple gallbladder polyps: Study protocol of multicentre, randomised, open-labelled, controlled trial","authors":"Tian Yang ,&nbsp;Ming-Da Wang ,&nbsp;Gui-Lin Xie ,&nbsp;Xiong-Hua Wang ,&nbsp;Liu Zheng ,&nbsp;Li-Min Wang ,&nbsp;Guang-Fa Xiao ,&nbsp;Yong-Qing Yang ,&nbsp;Chao Li ,&nbsp;Alfred Wei Chieh Kow ,&nbsp;Feng Shen","doi":"10.1016/j.iliver.2024.100127","DOIUrl":"10.1016/j.iliver.2024.100127","url":null,"abstract":"<div><h3>Introduction</h3><div>Gallbladder polyps (GPs) are protrusions of the gallbladder wall into the lumen, and are commonly detected during ultrasound examinations. Traditional management of multiple GPs (MGPs) has been conservative, including lifestyle interventions, regular monitoring, and surgical intervention in certain cases, but this approach poses risks of polyps enlargement and increase of number, as well as patients’ psychological burdens. Danning Tablets, a traditional Chinese medicine, have emerged as a potential non-surgical treatment for GPs, showing promise in reducing polyp size and alleviating symptoms, backed by their anti-inflammatory and antitumor properties demonstrated in preclinical studies. This suggests the need for further research into Danning Tablets as an alternative treatment for MGPs.</div></div><div><h3>Methods and analysis</h3><div>The study is designed as a prospective, randomized, controlled, open-label trial. The study will be conducted across multiple centres specializing in gastroenterology and hepatology. Participants will be recruited from these centres, ensuring a diverse patient demographic. Adult patients diagnosed with MGPs, based on ultrasound findings, will be included. Exclusion criteria include patients with a history of gallbladder cancer, previous gallbladder surgery, or serious comorbid conditions. The control group will receive standard care, including dietary and lifestyle advice, while the intervention group will receive Danning Tablets and standard care. The dosage and administration of Danning Tablets will follow established clinical guidelines. The primary outcome will be the change in size of the largest gallbladder polyps on week 24 ± 1, measured by ultrasound. The secondary outcomes will include symptom improvement and recording of any adverse events. The study will span over a period of 6 months, with periodic assessments at baseline, 4, 8, 12, and 24 weeks.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 4","pages":"Article 100127"},"PeriodicalIF":0.0,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142706991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Dr. Sun et al.: Female DILI patients need more clinical attention","authors":"Yu-Ting Xiong,&nbsp;Chun-Yan Wang,&nbsp;Dong Ji","doi":"10.1016/j.iliver.2024.100126","DOIUrl":"10.1016/j.iliver.2024.100126","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 4","pages":"Article 100126"},"PeriodicalIF":0.0,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142706993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased attention to women with drug-induced liver injury: Risk factors and early intervention","authors":"Xiaoru Sun ,&nbsp;Xinrong Zhang ,&nbsp;Muyun Liu","doi":"10.1016/j.iliver.2024.100125","DOIUrl":"10.1016/j.iliver.2024.100125","url":null,"abstract":"<div><div>A recent study by Xiong Yu-Ting and colleagues has unveiled the clinical characteristics and risk factors of acute drug-induced liver injury (DILI). Upon reading the article, we found that there are some differences between female and male patients with DILI in terms of clinical and pathological features, especially in the number of patients, the degree of liver inflammation, and the risk of autoimmune liver disease. Therefore, it is necessary to pay attention to female patients with DILI and their outcomes, and to intervene appropriately in advance. This article analyzes the reasons for the differences between female and male patients with DILI and makes recommendations for patient prognosis.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 4","pages":"Article 100125"},"PeriodicalIF":0.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142651488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Arginine methylation modification in the malignant progression of benign and malignant liver diseases","authors":"Jie-Zuo Huang ,&nbsp;Bei-Ning Qiao ,&nbsp;Dang-Chi Li ,&nbsp;Qiu-Rong Wei ,&nbsp;Zi-Jian Zhang","doi":"10.1016/j.iliver.2024.100124","DOIUrl":"10.1016/j.iliver.2024.100124","url":null,"abstract":"<div><div>The role of protein arginine methyltransferases (PRMTs) in benign and malignant liver diseases has garnered considerable attention. PRMTs play a key function in regulating protein methylation modification in diseases such as alcoholic fatty liver disease, metabolic dysfunction–associated steatotic liver disease, viral hepatitis, and hepatocellular carcinoma. This review explores the mechanisms of action of PRMTs in these diseases, with a focus on their effects on cell signaling, transcriptional regulation, cell proliferation, and metabolism. We also discuss potential therapeutic strategies targeting PRMTs and propose future research directions. This review helps deepen the understanding of the important role of arginine methylation modification in the malignant progression of liver diseases and provides guidance for future clinical treatment and drug development.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 4","pages":"Article 100124"},"PeriodicalIF":0.0,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142528996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gd-EOB-DTPA-enhanced MRI proves advantageous in selecting surgical candidates for patients with early-stage hepatocellular carcinoma: An analysis in terms of oncological outcomes","authors":"Zhiwei Ye ,&nbsp;Jing Zhao ,&nbsp;Dandan Hu ,&nbsp;Zhoutian Yang ,&nbsp;Jinbin Chen ,&nbsp;Li Xu ,&nbsp;Zhongguo Zhou ,&nbsp;Minshan Chen ,&nbsp;Yaojun Zhang","doi":"10.1016/j.iliver.2024.100117","DOIUrl":"10.1016/j.iliver.2024.100117","url":null,"abstract":"<div><h3>Background and aims</h3><div>To determine the value of preoperative Gd-EOB-DTPA-enhanced magnetic resonance imaging (MRI) in comparison with extracellular contrast agent MRI and CT in the selection of surgical candidates among patients with hepatocellular carcinoma (HCC), particularly in terms of oncological outcomes after hepatectomy.</div></div><div><h3>Methods</h3><div>This retrospective study included 542 consecutive patients who underwent radical hepatectomy for HCC. One group underwent preoperative Gd-EOB-DTPA-enhanced MRI, one group underwent contrast-enhanced CT, and one group underwent extracellular contrast agent MRI. We compared oncologic outcomes including recurrence free survival and overall survival between the three groups. Subgroup analyses were also performed to provide more specific candidates or beneficiaries for preoperative EOB-MRI.</div></div><div><h3>Results</h3><div>A total of 244 patients had tumor recurrence, with 55 in the EOB-MRI group, 106 in the Routine-MRI group, and 83 in the CT group (<em>p</em> = 0.010). The numbers with early recurrence (&lt;2 years) in each group were 40 (27.03%), 78 (35.78%), and 62 (35.22%), respectively (<em>p</em> = 0.018). The 1, 2, and 3-year recurrence-free survival (RFS) percentages were 82.4%, 73.0%, and 68.2% in the EOB-MRI group, 70.2%, 64.3%, and 56.9% in the Routine-MRI group, and 76.8%, 64.83%, and 58.9% in the CT group (<em>p</em> = 0.010). The 1, 2, and 3-year overall survival percentages were 89.19%, 83.11%, and 80.41% in the EOB-MRI group, 79.82%, 73.86%, and 67.44% in the Routine-MRI group, and 86.55%, 76.14%, and 69.32% in the CT group (<em>p</em> = 0.016). Subgroup analysis showed significant differences in RFS in patients with solitary tumor &lt;3 cm.</div></div><div><h3>Conclusion</h3><div>Preoperative EOB-MRI is superior to contrast-enhanced CT or extracellular contrast agent MRI for selecting surgical candidates at low risk of recurrence following hepatic resection for HCC.</div></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 4","pages":"Article 100117"},"PeriodicalIF":0.0,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142434033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}